CLINICAL TRIAL: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

CLINICAL TRIAL: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Overview of new clinical trial for patients with resectable pleural mesothelioma looking into benefits of immunotherapy treatment prior to surgery. The trial compares two arms: in one arm patients are treated with nivolumab only prior to surgery; in the other arm they are treated with nivolumab + ipilimumab. This interview is moderated by Buerkley Rose, MSN, RN of the University of Chicago Medicine, and features the principal investigator of the study, Patrick Forde, MD of Johns Hopkins. The interview also provides insight from two surgeons participating in the trial: Joseph Friedberg, MD of the University of Maryland Medical Center, and Richard Battafarano, MD, PhD of Johns Hopkins. More information about MesoTV is available at www.curemeso.org/mesotv. More information about the Mesothelioma Applied Research Foundation can be found at www.curemeso.org.